Skip to main content

Table 5 Summary of clinical care outcomes in 353 individuals with a diagnosis of chronic HCV infection

From: Hepatitis virus (HCV) diagnosis and access to treatment in a UK cohort

Treatment Status Patient Classification Number Percentage of treatment subgroupa Percentage of total cohort
Not yet treated
(n = 130)
Offered appointment but did not attend 46 35.4 13.0
Seen in another clinic (sexual health, prison, paediatrics) 32 24.6 9.1
Seen by hepatology but not on treatment waiting list 23 17.7 6.5
Seen by hepatology and on treatment waiting list for DAA 3 2.3 0.9
Died 11 8.5 3.1
Transferred out of area 10 7.7 2.8
Seen in clinic but lost to follow-up 2 1.5 0.6
Spontaneous clearer 3 2.3 0.8
Treated
with DAA (n = 59)
SVR12 50 84.7 14.2
Relapsed 4 6.8 1.1
Outcome data pending 5 8.5 1.4
Treated with IFN/RBV
(n = 20)
SVR12 16 80.0 4.5
Relapsed 3 15.0 0.8
No outcome data 1 5.0 0.3
Unknown
(n = 150)
Not known to local services 144 100 40.8
TOTAL   353 400 100
  1. aTreatment subgroup is defined as the four categories listed in the first column of this table. The total of this column is 300%, as the total for each of three subgroups is 100%
  2. DAA = direct acting antivirals, IFN = interferon, RBV = ribavirin; SVR12 = sustained viraemic response at ≥12 weeks following therapy
\